Skip to content
2000
  1. Home
  2. A-Z Publications
  3. New Emirates Medical Journal
  4. Volume 5, Issue 1
  5. Article
Volume 5, Issue 1
  • ISSN: 0250-6882
  • E-ISSN: 0250-6882
file format pdf download PDF
side by side viewer icon HTML

Abstract

Background

The association between visceral obesity and insulin resistance establishes an alternative risk for the onset of type 2 diabetes mellitus. The infiltration of macrophages in the visceral fatty tissue and the unreliable generation of adipokines are associated with mechanisms directing the progress of insulin resistance.

Objective

The objective of the study was to observe the relationship between visceral fat-associated adipokines and biochemical variables in central obese type 2 diabetic patients.

Methods

This study included 100 central obese subjects (both genders) aged 30-60 years newly diagnosed with type 2 diabetes mellitus. Out of the 100 participants, 73 were male and 27 were female. Serum adipokines were analyzed using an enzyme-linked immunosorbent assay. Biochemical parameters were assessed using the Cobas® 6000 analyzer, while HbA1c levels were determined through high-performance liquid chromatography.

Results

The results showed a significant relationship (p < 0.05) between the adipokines and HbA1c, fasting, and postprandial blood glucose levels. The results indicated a significant association (p < 0.05) between the adipokines and lipid profile with varying degrees in central obese type 2 diabetic subjects.

Conclusion

The relationship between visceral fat-associated adipokines and metabolic variables may influence the metabolic pathways in central obese type 2 diabetic patients. The adipokines are strong predictors for the intensification of diabetic risk and can be used as a diagnostic tool for risk assessment in the central obese population.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882293086240422102329
2024-05-03
2025-01-19

  • From This Site

    /content/journals/nemj/10.2174/0102506882293086240422102329
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/nemj/5/1/NEMJ-5-E02506882293086.html?itemId=/content/journals/nemj/10.2174/0102506882293086240422102329&mimeType=html&fmt=ahah

References

  1. International Diabetes FederationIDF Diabetes Atlas.9th edBrussels, BelgiumInternational Diabetes Federation2019
     [Google Scholar]
  2. Galicia-GarciaU. Benito-VicenteA. JebariS. Larrea-SebalA. SiddiqiH. UribeK.B. OstolazaH. MartínC. Pathophysiology of type 2 diabetes mellitus.Int. J. Mol. Sci.20202117627510.3390/ijms2117627532872570
     [Google Scholar]
  3. RychterA.M. Skrzypczak-ZielińskaM. ZielińskaA. EderP. SoutoE.B. ZawadaA. RatajczakA.E. DobrowolskaA. Krela-KaźmierczakI. Is the retinol-binding protein 4 a possible risk factor for cardiovascular diseases in obesity?Int. J. Mol. Sci.20202115522910.3390/ijms2115522932718041
     [Google Scholar]
  4. WondmkunY.T. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications.Diabetes Metab. Syndr. Obes.2020133611361610.2147/DMSO.S27589833116712
     [Google Scholar]
  5. XuH. JinC. GuanQ. Causal effects of overall and abdominal obesity on insulin resistance and the risk of type 2 diabetes mellitus: A two-sample Mendelian randomization study.Front. Genet.20201160310.3389/fgene.2020.0060332714368
     [Google Scholar]
  6. MoncanM. MnichK. BlommeA. AlmanzaA. SamaliA. GormanA.M. Regulation of lipid metabolism by the unfolded protein response.J. Cell. Mol. Med.20212531359137010.1111/jcmm.1625533398919
     [Google Scholar]
  7. OwolabiE.O. Ter GoonD. AdeniyiO.V. Central obesity and normal-weight central obesity among adults attending healthcare facilities in Buffalo City Metropolitan Municipality, South Africa: a cross-sectional study.J. Health Popul. Nutr.20173615410.1186/s41043‑017‑0133‑x29282137
     [Google Scholar]
  8. LeeY.J. KimJ.J. KimJ. ChoD.W. WonJ.Y. The Correlation between Waist Circumference and the Pro-Inflammatory Adipokines in Diabetic Retinopathy of Type 2 Diabetes Patients.Int. J. Mol. Sci.2023243203610.3390/ijms2403203636768360
     [Google Scholar]
  9. Kumar KhemkaV. BanerjeeA. Metabolic risk factors in obesity and diabetes mellitus: implications in the pathogenesis and therapy.Integr. Obes. Diabetes2017331410.15761/IOD.1000179
     [Google Scholar]
  10. TylutkaA. MorawinB. WalasŁ. MichałekM. GwaraA. Zembron-LacnyA. Assessment of metabolic syndrome predictors in relation to inflammation and visceral fat tissue in older adults.Sci. Rep.20231318910.1038/s41598‑022‑27269‑636596839
     [Google Scholar]
  11. PaleyC.A. JohnsonM.I. Abdominal obesity and metabolic syndrome: exercise as medicine?BMC Sports Sci. Med. Rehabil.2018101710.1186/s13102‑018‑0097‑129755739
     [Google Scholar]
  12. ShibataR. OuchiN. OhashiK. MuroharaT. The role of adipokines in cardiovascular disease.J. Cardiol.201770432933410.1016/j.jjcc.2017.02.00628325521
     [Google Scholar]
  13. ChaitA. den HartighL.J. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease.Front. Cardiovasc. Med.202072210.3389/fcvm.2020.0002232158768
     [Google Scholar]
  14. Al-SulaitiH. DibounI. AghaM.V. MohamedF.F.S. AtkinS. DömlingA.S. ElrayessM.A. MazloumN.A. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes.J. Transl. Med.201917134810.1186/s12967‑019‑2096‑831640727
     [Google Scholar]
  15. FanJ. YinS. LinD. LiuY. ChenN. BaiX. KeQ. ShenJ. YouL. LinX. LiF. HeF. YanL. ChenC. XiaM. Association of serum retinol-binding protein 4 levels and the risk of incident type 2 diabetes in subjects with Prediabetes.Diabetes Care20194281574158110.2337/dc19‑026531186297
     [Google Scholar]
  16. ZhangY. HuoY. HeW. LiuS. LiH. LiL. Visfatin is regulated by interleukin‑6 and affected by the PPAR‑γ pathway in BeWo cells.Mol. Med. Rep.201919140040630483779
     [Google Scholar]
  17. ZhengL.Y. XuX. WanR.H. XiaS. LuJ. HuangQ. Association between serum visfatin levels and atherosclerotic plaque in patients with type 2 diabetes.Diabetol. Metab. Syndr.20191116010.1186/s13098‑019‑0455‑531367237
     [Google Scholar]
  18. HeoY.J. ChoiS.E. JeonJ.Y. HanS.J. KimD.J. KangY. LeeK.W. KimH.J. Visfatin induces inflammation and insulin resistance via the NF-KB and STAT3 signaling pathways in hepatocytes.J. Diabetes Res.2019201911110.1155/2019/402162331396538
     [Google Scholar]
  19. AchariA. JainS. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction.Int. J. Mol. Sci.2017186132110.3390/ijms1806132128635626
     [Google Scholar]
  20. Forny-GermanoL. De FeliceF.G. VieiraM.N.N. The role of leptin and adiponectin in obesity-associated cognitive decline and alzheimer’s disease.Front. Neurosci.201912102710.3389/fnins.2018.0102730692905
     [Google Scholar]
  21. ShaheerA. KumarA. MenonP. JalloM. BashaS. Effect of add-on therapy of sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on adipokines in type 2 diabetes mellitus.J. Clin. Med. Res.202113635536210.14740/jocmr451034267843
     [Google Scholar]
  22. UnamunoX. Gómez-AmbrosiJ. RodríguezA. BecerrilS. FrühbeckG. CatalánV. Adipokine dysregulation and adipose tissue inflammation in human obesity.Eur. J. Clin. Invest.2018489e1299710.1111/eci.1299729995306
     [Google Scholar]
  23. ZorenaK. Jachimowicz-DudaO. ŚlęzakD. RobakowskaM. MrugaczM. Adipokines and obesity. potential link to metabolic disorders and chronic complications.Int. J. Mol. Sci.20202110357010.3390/ijms2110357032443588
     [Google Scholar]
  24. NeelandI.J. PoirierP. DesprésJ.P. Cardiovascular and metabolic heterogeneity of obesity.Circulation2018137131391140610.1161/CIRCULATIONAHA.117.02961729581366
     [Google Scholar]
  25. WangX. HuangY. GaoJ. SunH. JayachandranM. QuS. Changes of serum retinol-binding protein 4 associated with improved insulin resistance after laparoscopic sleeve gastrectomy in Chinese obese patients.Diabetol. Metab. Syndr.2020121710.1186/s13098‑019‑0511‑131956345
     [Google Scholar]
  26. LauW.B. OhashiK. WangY. OgawaH. MuroharaT. MaX.L. OuchiN. Role of adipokines in cardiovascular disease.Circ. J.201781792092810.1253/circj.CJ‑17‑045828603178
     [Google Scholar]
  27. TrojnarM. Patro-MałyszaJ. Kimber-TrojnarŻ. Leszczyńska-GorzelakB. MosiewiczJ. Associations between fatty acid-binding protein 4–a proinflammatory Adipokine and insulin resistance, gestational and type 2 diabetes mellitus.Cells20198322710.3390/cells803022730857223
     [Google Scholar]
  28. ZhangL. ChengY.L. XueS. XuZ.G. The role of circulating RBP4 in the type 2 diabetes patients with kidney diseases: A systematic review and meta-analysis.Dis. Markers2020202011210.1155/2020/883047133082885
     [Google Scholar]
  29. SaitoN. FuruhashiM. KoyamaM. HigashiuraY. AkasakaH. TanakaM. MoniwaN. OhnishiH. SaitohS. UraN. ShimamotoK. MiuraT. Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: A 12-year prospective study.Sci. Rep.2021111400810.1038/s41598‑021‑83494‑533597568
     [Google Scholar]
  30. NakamuraR. OkuraT. FujiokaY. SumiK. MatsuzawaK. IzawaS. UetaE. KatoM. TaniguchiS. YamamotoK. Serum fatty acid-binding protein 4 (FABP4) concentration is associated with insulin resistance in peripheral tissues, A clinical study.PLoS One2017126e017973710.1371/journal.pone.017973728654680
     [Google Scholar]
  31. LandechoM.F. TueroC. ValentíV. BilbaoI. de la HigueraM. FrühbeckG. Relevance of leptin and other adipokines in obesity-associated cardiovascular risk.Nutrients20191111266410.3390/nu1111266431694146
     [Google Scholar]
  32. FrankenbergA.D. ReisA.F. GerchmanF. Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: A literature review.Arch. Endocrinol. Metab.201761661462210.1590/2359‑399700000031629412387
     [Google Scholar]
  33. GariballaS. AlkaabiJ. YasinJ. Al EssaA. Total adiponectin in overweight and obese subjects and its response to visceral fat loss.BMC Endocr. Disord.20191915510.1186/s12902‑019‑0386‑z31159801
     [Google Scholar]
/content/journals/nemj/10.2174/0102506882293086240422102329
Loading
Visceral Fat-associated Adipokines and Metabolic Variables in Central Obese Type 2 Diabetic Patients
NEW Emirates Medical J 5, e02506882293086 (2024); https://doi.org/10.2174/0102506882293086240422102329
/content/journals/nemj/10.2174/0102506882293086240422102329
/content/journals/nemj/10.2174/0102506882293086240422102329
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Adipokines; Adiponectin; Cytokines; Diabetes; Obesity; Visfatin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test